Jason M. Broderick

Experts from ASCO detail the organization's response to the COVID-19 crisis and resources available for its members.

Tocilizumab, a treatment used for adverse events related to cancer therapy, among other indications, is being explored in a phase III trial as a treatment for adult patients hospitalized with severe COVID-19 pneumonia, according to Genentech (Roche), the manufacturer of the interleukin-6 receptor antagonist.

Olaparib has received an orphan drug designation in Japan for the maintenance treatment of germline BRCA-mutated curatively unresectable pancreatic cancer.

Topline results from the pivotal phase III FLASH trial showed that SGX301 demonstrated strong clinical activity in patients with cutaneous T-cell lymphoma.

The Chinese National Medical Products Administration has approved almonertinib (Ameile; HS-10296) for the treatment of patients with EGFR T790M mutation–positive non–small cell lung cancer who have progressed on or after other EGFR TKI therapy.

The FDA has granted 2 Orphan Drug Designations to ALPN-101 for the prevention and treatment of acute graft-versus-host-disease.

Combining durvalumab with standard frontline chemotherapies showed a sustained overall survival benefit in patients with extensive-stage small cell lung cancer, but a regimen of durvalumab, chemotherapy, and tremelimumab did not boost OS.

Haploidentical allogeneic stem cell transplant is a viable treatment option for patients with myelofibrosis who have a higher risk for posttransplant complications and mortality.

The China National Medical Products Administration has accepted a supplemental New Drug Application for niraparib for use as a frontline maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

The phase III JAVELIN Head and Neck 100 trial has been terminated after an interim analysis showed that the addition of avelumab to standard-of-care chemoradiotherapy was unlikely to lead to a statistically significant improvement in progression-free survival in patients with untreated locally advanced squamous cell carcinoma of the head and neck.

The FDA has granted a Fast Track designation to the combination of the PD-1 inhibitor balstilimab and the CTLA-inhibitor zalifrelimab for the treatment of patients with relapsed or refractory metastatic cervical cancer.

The FDA has approved the CINtec PLUS Cytology test as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus using the cobas 4800 HPV Test.

Adjuvant platinum-based chemotherapy reduced the risk of disease recurrence or death by 55% in patients with upper tract urothelial carcinoma, according to findings from the phase III POUT trial that have now been published in The Lancet.

Larotrectinib continued to show strong tumor-agnostic efficacy in patients with TRK fusion–positive cancers, according to results from an integrated analysis of 3 clinical trials.

The FDA has granted an orphan drug designation to umbralisib for the treatment of patients with follicular lymphoma.

Researchers at the Mayo Clinic maintain that all women aged 65 or under with a breast cancer diagnosis should receive germline genetic testing to identify harmful mutations that increase their risk of developing secondary cancers.

The antidepressant phenelzine showed antitumor activity in patients with biochemical recurrent castrate-sensitive prostate cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a Marketing Authorization Application for brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer

Combining venetoclax with low-dose cytarabine (LDAC) did not lead to a statistically significant improvement in overall survival compared with LDAC alone in newly-diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy, according to findings from the phase III VIALE-C (M16-043) trial.

At the 24th Annual International Congress on Hematologic Malignancies®, Sonali M. Smith, MD, detailed the critical clinical trial findings currently informing treatment selection in the frontline indolent non-Hodgkin lymphoma paradigm.

The FDA has accepted a Biologics License Application for a fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase, administered by subcutaneous injection in combination with intravenous chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer.

The FDA has accepted a supplemental New Drug Application for niraparib for use as a frontline maintenance treatment for women with advanced ovarian cancer who responded to platinum-based chemotherapy regardless of biomarker status.

The FDA has granted a priority review designation to a supplemental New Drug Application for brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer.

The Japanese Ministry of Health, Labor and Welfare has approved nivolumab for the treatment of patients with unresectable advanced or recurrent esophageal cancer that has progressed following chemotherapy.

The FDA has granted a priority review designation to a supplemental new drug application for tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma who have received at least 2 prior lines of systemic therapy.

The FDA has granted a priority review designation to a new drug application for cedazuridine plus decitabine for the treatment of adult patients with previously untreated intermediate- and high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

The FDA has granted a priority review designation to a new drug application for tucatinib for use in combination with trastuzumab and capecitabine for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including patients with brain metastases, following at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant, or metastatic setting.

The FDA has granted a priority review designation to a new drug application for ripretinib for the treatment of patients with advanced gastrointestinal stromal tumors.

A supplemental Biologics License Application has been submitted to the FDA for daratumumab for use in combination with carfilzomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma.

The FDA has granted a priority review designation to a new drug application for capmatinib for use as treatment for newly diagnosed and previously treated patients with locally advanced or metastatic MET exon14 skipping—mutated non–small cell lung cancer.